View Financial HealthNascent Pharma Holdings 배당 및 자사주 매입배당 기준 점검 0/6Nascent Pharma Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 17Can B Corp. Files Form 15Can B Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, no par value under the Securities Exchange Act of 1934, as amended.공고 • Mar 29Can B Corp. announced delayed annual 10-K filingOn 03/28/2025, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Oct 29Can B Files A Certificate on Form 15 with the U.S. Securities and Exchange CommissionOn October 25, 2024, Can B Corp. (‘Can B’) implemented a holding company reorganization (the ‘Nascent Merger’) pursuant to the Agreement and Plan of Merger (the ‘Merger Agreement’), dated as of October 23, 2024, among Can B, Nascent Pharma Holdings Inc. (‘Nascent’), and Nascent Merger Sub Inc. (‘Merger Sub’), which resulted in Nascent owning all of the outstanding capital stock of Can B. Pursuant to the Nascent Merger, Merger Sub, a direct, wholly owned subsidiary of Nascent and an indirect, wholly owned subsidiary of Can B, merged with and into Can B, with Can B surviving as a direct, wholly owned subsidiary of Nascent. Each share of each class of Can B stock issued and outstanding immediately prior to the Nascent Merger automatically converted into an equivalent corresponding share of Nascent stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Can B stock being converted. Accordingly, upon consummation of the Nascent Merger, Can B’s stockholders immediately prior to the consummation of the Nascent Merger became stockholders of Nascent. The stockholders of Can B will not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares in the Nascent Merger. In connection with the Nascent Merger, Can B notified the Financial Industry Regulatory Authority (‘FINRA’) that it planned to complete the Nascent Merger and, in connection therewith, requested that a new trading symbol be assigned to Nascent. FINRA requested that a new notice be submitted to FINRA after the Nascent Merger is complete. As a result, the change in issuer name and trading symbol on the OTCQB Market will not occur until FINRA completes the processing of the name change and assigns Nascent a trading symbol. On October 28, 2024, Can B filed a certificate on Form 15 with the U.S. Securities and Exchange Commission (the ‘Commission’) under the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’) requesting that Can B shares be deregistered under the Exchange Act, and that Can B’s reporting obligations under the Exchange Act be suspended (except to the extent of the succession of Nascent to the Exchange Act Section 12(g) registration and reporting obligations of Can B).공고 • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 18Can B Corp. announced delayed 10-Q filingOn 05/16/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Mar 30Can B Corp. announced delayed annual 10-K filingOn 03/29/2024, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Oct 12Can B Corp. Announces its Move and Consolidation of its Pure Health Product Operations from Lacey, WA to ColoradoCan B Corp. announced its move and consolidation of its Pure Health Product operations from Lacey, WA to Colorado. This furthers Can B’s corporate consolidations as it previously did with Miami and McMinville operations also relocating to Colorado. The move included relocating all of the Superfood products manufacturing, process, packaging, labeling, and raw materials/ingredients for Integrity Brands by Brooke Burke Body and other brands to the Company’s Fort Morgan facility on County Road 21, known as the “Budweiser Building.” Pure Health Products expects to have the Superfood production in full operation by mid-October 2023. The other production equipment, including bottling lines, capsule machines, tablet presses, coating machines, wet and dry pouch machines, and various packing sealing and coding equipment, was split into two segments between Hakala Research, LLC in Glen Rock, Wyoming, under a use agreement and CO Botanicals building on Energy Road in Fort Morgan, CO known as the “ICS Building.” This equipment will continue production of PHP’s white-label and brand-labeled tinctures, salves, roll-ons, oils, supplements, lotions, and related products, both with and without CBD. This equipment is expected to be operational by the end of October 2023 as the Company also has sufficient products in inventory to meet expected demand for 45-60 days at current usage.공고 • May 16Can B Corp. announced delayed 10-Q filingOn 05/15/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Nov 15Can B Corp. announced delayed 10-Q filingOn 11/14/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Aug 16Can B Corp. announced delayed 10-Q filingOn 08/15/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 17Can B Corp. announced delayed 10-Q filingOn 05/16/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 06Can B Corp. announced delayed annual 10-K filingOn 04/04/2022, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Aug 26Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville.Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville on August 25, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of 300,000 Square Foot Facility In McMinnville on August 25, 2021.공고 • May 18Can B Corp. announced delayed 10-Q filingOn 05/17/2021, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 30Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech.Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech on April 29, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of Pharmacokinetics Tech on April 29, 2021.공고 • Apr 02Can B Corp. announced delayed annual 10-K filingOn 03/31/2021, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Feb 19Can B Corp Partners with Signature PR to Launch a New Premier LineCan B Corp. announced its partnership with Signature PR to initiate efforts for the launch of a new premier line. Under the leadership of Annamarie Seabright, Signature PR is developing an expansion plan into spas, salons, high-end retailers, hospitality services and others.공고 • Feb 11Can B Corp and Dr. Karl Zarse Launches ImmuneX2Can B Corp. announced that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing immune system before need it. The certified organic twice a day AM/PM supplement is developed by a physician and prepackaged for convenient dosing. Consumers have the option for a monthly subscription with auto-renewal for a discount to the suggested retail price via the ImmuneX2 website. Pure Health Products, LLC, a subsidiary of Can B, is manufacturing ImmuneX2 for production under Dr. Zarse’s ImmuneX2 label. Can B will utilize its existing and growing professional medical sales channel that it has built over the past few years with its lineup of other health and wellness branded products, including Duramed and Canbiola to promote ImmuneX2.공고 • Sep 24Can B Corp. announced that it has received $0.104 million in funding from EMA Financial LLCCan B Corp. (OTCPK:CANB) announced that it has entered into a securities purchase agreement with EMA Financial LLC to issue a 12% Convertible Promissory Note of the principal amount of $115,000 for gross proceeds of $104,000 on a best efforts basis, on June 15, 2020. The note is issued at an original issuance discount of $11,000 and bear an interest at 12% per year and matures on June 17, 2021. The note is convertible into shares at a price per share equal to 80% of the lowest closing bid price of the company’s common stock during the twenty trading days prior to the date of conversion. The company raised funding through exemption provided under Regulation D.공고 • Sep 23Can B Corp. announced that it has received $0.204545 million in funding from The EquiLux Group, LPOn May 12, 2020, Can B Corp. (OTCPK:CANB) closed the transaction. The company issued securities pursuant to exemption provided under Regulation D.공고 • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2020, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NASC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NASC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Nascent Pharma Holdings 배당 수익률 vs 시장NASC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NASC)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.0%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (NASC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NASC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NASC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NASC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NASC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/04 08:11종가2026/08/04 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nascent Pharma Holdings, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관William GregozeskiGreenridge Global LLC
공고 • Jul 17Can B Corp. Files Form 15Can B Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, no par value under the Securities Exchange Act of 1934, as amended.
공고 • Mar 29Can B Corp. announced delayed annual 10-K filingOn 03/28/2025, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Oct 29Can B Files A Certificate on Form 15 with the U.S. Securities and Exchange CommissionOn October 25, 2024, Can B Corp. (‘Can B’) implemented a holding company reorganization (the ‘Nascent Merger’) pursuant to the Agreement and Plan of Merger (the ‘Merger Agreement’), dated as of October 23, 2024, among Can B, Nascent Pharma Holdings Inc. (‘Nascent’), and Nascent Merger Sub Inc. (‘Merger Sub’), which resulted in Nascent owning all of the outstanding capital stock of Can B. Pursuant to the Nascent Merger, Merger Sub, a direct, wholly owned subsidiary of Nascent and an indirect, wholly owned subsidiary of Can B, merged with and into Can B, with Can B surviving as a direct, wholly owned subsidiary of Nascent. Each share of each class of Can B stock issued and outstanding immediately prior to the Nascent Merger automatically converted into an equivalent corresponding share of Nascent stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Can B stock being converted. Accordingly, upon consummation of the Nascent Merger, Can B’s stockholders immediately prior to the consummation of the Nascent Merger became stockholders of Nascent. The stockholders of Can B will not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares in the Nascent Merger. In connection with the Nascent Merger, Can B notified the Financial Industry Regulatory Authority (‘FINRA’) that it planned to complete the Nascent Merger and, in connection therewith, requested that a new trading symbol be assigned to Nascent. FINRA requested that a new notice be submitted to FINRA after the Nascent Merger is complete. As a result, the change in issuer name and trading symbol on the OTCQB Market will not occur until FINRA completes the processing of the name change and assigns Nascent a trading symbol. On October 28, 2024, Can B filed a certificate on Form 15 with the U.S. Securities and Exchange Commission (the ‘Commission’) under the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’) requesting that Can B shares be deregistered under the Exchange Act, and that Can B’s reporting obligations under the Exchange Act be suspended (except to the extent of the succession of Nascent to the Exchange Act Section 12(g) registration and reporting obligations of Can B).
공고 • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 18Can B Corp. announced delayed 10-Q filingOn 05/16/2024, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Mar 30Can B Corp. announced delayed annual 10-K filingOn 03/29/2024, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Nov 14Can B Corp. announced delayed 10-Q filingOn 11/13/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Oct 12Can B Corp. Announces its Move and Consolidation of its Pure Health Product Operations from Lacey, WA to ColoradoCan B Corp. announced its move and consolidation of its Pure Health Product operations from Lacey, WA to Colorado. This furthers Can B’s corporate consolidations as it previously did with Miami and McMinville operations also relocating to Colorado. The move included relocating all of the Superfood products manufacturing, process, packaging, labeling, and raw materials/ingredients for Integrity Brands by Brooke Burke Body and other brands to the Company’s Fort Morgan facility on County Road 21, known as the “Budweiser Building.” Pure Health Products expects to have the Superfood production in full operation by mid-October 2023. The other production equipment, including bottling lines, capsule machines, tablet presses, coating machines, wet and dry pouch machines, and various packing sealing and coding equipment, was split into two segments between Hakala Research, LLC in Glen Rock, Wyoming, under a use agreement and CO Botanicals building on Energy Road in Fort Morgan, CO known as the “ICS Building.” This equipment will continue production of PHP’s white-label and brand-labeled tinctures, salves, roll-ons, oils, supplements, lotions, and related products, both with and without CBD. This equipment is expected to be operational by the end of October 2023 as the Company also has sufficient products in inventory to meet expected demand for 45-60 days at current usage.
공고 • May 16Can B Corp. announced delayed 10-Q filingOn 05/15/2023, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Nov 15Can B Corp. announced delayed 10-Q filingOn 11/14/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Aug 16Can B Corp. announced delayed 10-Q filingOn 08/15/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 17Can B Corp. announced delayed 10-Q filingOn 05/16/2022, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 06Can B Corp. announced delayed annual 10-K filingOn 04/04/2022, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Aug 26Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville.Can B Corp. (OTCPK:CANB) acquired 300,000 Square Foot Facility In McMinnville on August 25, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of 300,000 Square Foot Facility In McMinnville on August 25, 2021.
공고 • May 18Can B Corp. announced delayed 10-Q filingOn 05/17/2021, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 30Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech.Can B Corp. (OTCPK:CANB) acquired Pharmacokinetics Tech on April 29, 2021. Can B Corp. (OTCPK:CANB) completed the acquisition of Pharmacokinetics Tech on April 29, 2021.
공고 • Apr 02Can B Corp. announced delayed annual 10-K filingOn 03/31/2021, Can B Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Feb 19Can B Corp Partners with Signature PR to Launch a New Premier LineCan B Corp. announced its partnership with Signature PR to initiate efforts for the launch of a new premier line. Under the leadership of Annamarie Seabright, Signature PR is developing an expansion plan into spas, salons, high-end retailers, hospitality services and others.
공고 • Feb 11Can B Corp and Dr. Karl Zarse Launches ImmuneX2Can B Corp. announced that its partnership with Dr. Karl Zarse has launched ImmuneX2, a super immune boosting twice a day AM/PM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing immune system before need it. The certified organic twice a day AM/PM supplement is developed by a physician and prepackaged for convenient dosing. Consumers have the option for a monthly subscription with auto-renewal for a discount to the suggested retail price via the ImmuneX2 website. Pure Health Products, LLC, a subsidiary of Can B, is manufacturing ImmuneX2 for production under Dr. Zarse’s ImmuneX2 label. Can B will utilize its existing and growing professional medical sales channel that it has built over the past few years with its lineup of other health and wellness branded products, including Duramed and Canbiola to promote ImmuneX2.
공고 • Sep 24Can B Corp. announced that it has received $0.104 million in funding from EMA Financial LLCCan B Corp. (OTCPK:CANB) announced that it has entered into a securities purchase agreement with EMA Financial LLC to issue a 12% Convertible Promissory Note of the principal amount of $115,000 for gross proceeds of $104,000 on a best efforts basis, on June 15, 2020. The note is issued at an original issuance discount of $11,000 and bear an interest at 12% per year and matures on June 17, 2021. The note is convertible into shares at a price per share equal to 80% of the lowest closing bid price of the company’s common stock during the twenty trading days prior to the date of conversion. The company raised funding through exemption provided under Regulation D.
공고 • Sep 23Can B Corp. announced that it has received $0.204545 million in funding from The EquiLux Group, LPOn May 12, 2020, Can B Corp. (OTCPK:CANB) closed the transaction. The company issued securities pursuant to exemption provided under Regulation D.
공고 • Aug 15Can B Corp. announced delayed 10-Q filingOn 08/14/2020, Can B Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.